HK's Biostime to buy Australian vitamin maker Swisse for over US$1b: media
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
[SYDNEY] Hong Kong-listed dietary supplements company Biostime International Holdings has agreed to buy Australian vitamin maker Swisse Wellness for more than A$1.5 billion (S$1.5 billion), Australian media reported on Thursday.
The company beat Shanghai Pharmaceuticals Holding and Chinese private equity firm Hony Capital in a sale managed by Goldman Sachs Group Inc, the Australian newspaper and Fairfax Media said in reports, citing unnamed sources.
Swisse and Goldman Sachs were not immediately available for comment. Biostime issued a statement saying it had requested a trading halt for its shares, without giving an explanation.
REUTERS
Share with us your feedback on BT's products and services
TRENDING NOW
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Beijing’s calculated silence on the Iran war
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance
